Pharmacokinetic evaluation showed that, when tumor patients were separately treated with low-dose 100 mg of Plk1 inhibitors and high-dose 200 mg of Plk1 inhibitors, there were no significant difference in total plasma clearance, terminal half-life, and apparent distribution volume of inhibitors in homeostasis. The gene discussed is PLK1; the disease is neoplasm.